plant
provid
mankind
use
molecul
centuri
idea
produc
heterolog
exogen
nonplant
protein
plant
get
plantmad
pharmaceut
pmp
avail
rapidli
advanc
year
et
al
first
plantmad
pharmaceut
relev
protein
human
growth
hormon
express
transgen
tobacco
barta
et
al
human
protein
produc
increas
varieti
plant
speci
techniqu
express
first
antibodi
tobacco
hiatt
et
al
subsequ
product
first
experiment
plantmad
vaccin
eg
hepat
b
viru
surfac
antigen
mason
et
al
clearli
show
plant
capabl
assembl
function
glycoprotein
complex
structur
structur
authent
preserv
function
plantproduc
recombin
protein
confirm
product
complex
antibodi
deriv
secretori
immunoglobulin
et
al
new
immunogen
protein
haq
et
al
also
antigen
peptid
express
fusion
plant
viral
coat
protein
made
mani
case
assembl
virallik
particl
demonstr
abl
protect
anim
challeng
pathogen
epitop
deriv
rybicki
kushnir
et
al
time
fusion
plantderiv
protein
planttyp
sequenc
found
improv
immunogen
antigen
vaccin
tumour
massa
et
al
evolut
molecular
techniqu
led
develop
system
like
gatewaymedi
clone
review
dafnyyelin
tzfira
golden
gate
binder
et
al
goldenbraid
sarrionperdigon
et
al
name
thank
even
assembl
multimodular
construct
express
multipl
protein
enzym
plant
possibl
besid
protein
pharmacolog
use
also
plantmad
industri
product
pmip
produc
enzym
protein
research
use
nutrit
supplement
polym
etc
davi
tschofen
et
al
unlik
mammalian
cellderiv
drug
plantderiv
antibodi
vaccin
pharmacolog
relev
protein
particularli
advantag
free
mammalian
viral
vector
andor
human
pathogen
advantag
offer
plant
may
includ
also
low
cost
cultiv
high
biomass
product
rel
fast
genetoprotein
time
low
invest
cost
good
scalabl
eukaryot
posttransl
modif
high
protein
yield
tabl
avail
effect
technic
mean
express
protein
plant
offer
prospect
use
bioreactor
product
costeffect
pharmaceut
human
anim
health
sector
past
four
decad
wealth
literatur
demonstr
product
protein
plant
health
applic
promis
approach
area
biolog
manufactur
hope
togeth
defin
mit
technolog
review
biggest
biotech
discoveri
centuri
crispr
technolog
new
frontier
biomed
discoveri
rang
pharmaceut
sector
agroindustri
open
readi
nextgener
plantbas
medicin
intent
present
review
thought
make
point
evid
opportun
aris
farm
pharm
biolog
plant
properli
address
technolog
destin
tackl
human
anim
diseas
break
limit
current
standard
product
technolog
biopharmaceut
turn
help
reduc
dispar
health
right
guarante
better
health
protect
name
guid
principl
reduct
cost
stabl
nuclear
chloroplast
transform
two
approach
use
stabli
express
heterolog
ie
non
plant
recombin
protein
plant
agrobacteriummedi
particl
bombardmentmedi
stabl
transform
long
histori
achiev
stabl
integr
dna
plant
genom
result
express
transgen
tinland
field
wholepl
transform
mainli
tobacco
rel
nicotiana
benthamiana
fast
growth
rate
appar
defect
rna
silenc
system
goodin
et
al
potato
tomato
lettuc
main
leafi
crop
use
primari
advantag
abund
leaf
biomass
accumul
accompani
express
exogen
protein
tremblay
et
al
among
cereal
maiz
rice
barley
nandi
et
al
sabalza
et
al
tri
along
soybean
among
legum
wateri
tissu
leav
impos
extract
rapidli
target
protein
order
minim
degrad
desicc
seed
allow
protein
remain
stabl
suitabl
possibl
oral
administr
despit
larg
array
plant
system
avail
great
advantag
play
semin
role
develop
green
bioreactor
wholepl
transgen
approach
labourintens
timeconsum
due
necessari
step
plant
regener
select
averag
lead
time
rang
month
engin
plant
often
show
noncompetit
content
target
protein
gleba
et
al
stabl
introduct
target
gene
chloroplast
genom
transplastom
allow
higher
level
express
compar
nuclear
transform
due
lack
gene
silenc
phenomena
high
gene
copi
number
techniqu
also
advantag
sinc
prevent
possibl
transgen
escap
plastid
inherit
matern
tissu
major
speci
absenc
chloroplast
pollen
improb
transfer
quell
environment
concern
meyer
et
al
cardi
et
al
method
allow
high
concentr
recombin
protein
oey
et
al
nevertheless
technic
difficult
sinc
sever
gener
plant
regener
need
select
transform
plant
chloroplast
bear
gene
interest
homoplasm
state
addit
platform
lack
posttransl
modif
success
limit
number
speci
aquat
plant
like
duckwe
lemna
minor
nonvascular
plant
moss
physcomitrella
paten
consid
altern
express
platform
reski
et
al
properti
common
terrestri
plant
differenti
whole
plant
cell
suspens
cultur
grown
contain
simpl
medium
technolog
applic
aquat
plant
cell
suspens
cultur
similar
differ
aquat
plant
requir
light
cell
suspens
cultur
usual
grown
dark
addit
carbon
sourc
remov
cell
wall
gene
transfer
result
protoplast
suspens
cultur
easier
method
comparison
wholepl
genet
manipul
sinc
might
simplifi
purif
downstream
process
santo
et
al
addit
suspens
cultur
allow
homogen
cell
protein
sugar
nglycan
due
high
uniform
type
cell
size
lienard
et
al
plant
cell
cultiv
asept
use
classic
ferment
technolog
easi
scale
must
compli
regulatori
requir
similar
establish
consolid
system
base
microbi
mammalian
cell
fact
plant
suspens
cultur
made
singl
cell
allow
comparison
mostli
use
mammalian
cell
product
recombin
pharmaceut
chines
hamster
ovari
cho
cell
tabl
cellspecif
product
rate
pgcellday
report
monoclon
antibodi
produc
tobacco
cell
havenith
et
al
compar
typic
product
rate
pgcellday
cho
cell
typic
carri
thousand
gene
copi
show
differ
system
less
order
magnitud
santo
et
al
tobacco
cell
line
use
produc
mani
recombin
protein
ullisch
et
al
platform
includ
carrot
daucu
carota
rice
oryza
sativa
cell
line
hellwig
et
al
xu
et
al
innov
method
also
develop
product
cell
pack
suspens
cultur
facilit
accumul
purif
target
protein
rademach
notic
taligluceras
alfa
first
plantmad
licens
recombin
pharmaceut
protein
produc
carrot
cell
suspens
cultur
shaaltiel
et
al
well
veterinari
vaccin
poultri
newcastl
diseas
approv
us
depart
agricultur
produc
suspensioncultur
tobacco
cell
despit
gener
concern
possibl
genet
instabl
plant
cell
cultur
fundament
reliabl
system
medium
optim
process
engin
experimentalprocess
design
scaleup
tune
demand
review
santo
et
al
recent
past
system
devis
easili
contain
propag
transform
produc
recombin
protein
protein
express
system
base
unicellular
green
alga
chlamydomona
reinhardtii
develop
mayfield
et
al
alga
nuclear
plastidi
mitochondri
genom
complet
sequenc
system
chloroplasttarget
transgen
use
express
differ
recombin
healthrel
protein
like
bacteria
chloroplast
lack
machineri
perform
complex
posttransl
modif
glycosyl
glycosyl
protein
come
endoplasm
reticulum
unlik
e
coli
chlamydomona
chloroplast
allow
disulphid
bond
format
abl
carri
type
phosphoryl
unlik
higher
plant
c
reinhardtii
singl
chloroplast
genom
copi
consequ
convers
copi
chloroplast
genom
recombin
homoplasmi
facilit
complex
molecul
fulli
function
antibodi
therapeut
among
candid
therapeut
vaccin
human
papillomavirusrel
tumour
base
solubl
immunogen
form
viral
protein
biolog
produc
variou
yield
highlight
potenti
microalga
altern
platform
product
biolog
human
use
mayfield
et
al
demurta
et
al
rel
novel
platform
offer
advantag
includ
short
time
transform
scalingup
rapid
growth
doubl
time
hour
eas
cultiv
safeti
microalga
harbour
human
pathogen
mani
gener
regard
safe
gra
organ
facilit
product
biopharmaceut
gmp
condit
homogen
protein
product
technolog
molecular
pharm
c
reinhardtii
still
infanc
effort
made
bring
product
level
compar
wellestablish
platform
togeth
cell
suspens
organ
cultur
hairi
root
offer
advantag
includ
contain
defin
cultiv
condit
product
homogen
schillberg
et
al
hairi
root
hr
particularli
attract
industrialscal
product
secondari
metabolit
also
pharmaceut
protein
fact
like
undifferenti
cell
grow
simpl
defin
media
genet
stabl
easi
handl
protocol
avail
establish
transgen
line
highli
scalabl
produc
signific
biomass
accumul
guillon
et
al
hr
cultur
gener
agrobacterium
rhizogen
infect
infect
lead
gener
root
clone
character
extens
secondari
branch
cultiv
contain
steril
condit
hormonefre
media
franconi
et
al
importantli
recombin
protein
secret
cultur
medium
facilit
downstream
purif
process
guillon
et
al
hr
use
express
rang
recombin
protein
enzym
wood
et
al
vaccin
skarjinskaia
et
al
monoclon
antibodi
wongsamuth
doran
antihiv
microbicid
drake
et
al
edit
genom
plant
without
introduc
foreign
dna
cell
realiti
programm
nucleas
like
zincfing
nucleas
zfn
transcript
activatorlik
effector
nucleas
talen
rnaguid
endonucleas
use
genom
edit
plant
cell
amplifi
horizon
plant
molecular
farm
li
et
al
et
al
nekrasov
et
al
recent
crispr
cluster
regularli
interspac
short
palindrom
repeat
crisprassoci
system
success
use
wide
rang
plant
speci
bortesi
fischer
plant
suspens
cell
system
base
short
rna
guid
sgrna
associ
endonucleas
creat
doublestrand
break
dsb
target
genom
dna
consequ
mutat
gener
either
errorpron
nonhomolog
endjoin
nhej
homologydirect
repair
hdr
intend
cleavag
site
nhej
use
gener
mutagen
insertionsdelet
often
lead
gene
inactiv
result
chang
chromosom
target
site
indistinguish
natur
occur
genet
variat
howev
system
use
introduc
larger
modif
insert
exogen
sequenc
moreov
similar
tradit
gene
insert
tumefacien
use
deliveri
vector
result
genomeedit
plant
contain
foreign
dna
sequenc
addit
encod
programm
nucleas
host
genom
hand
use
episom
plasmid
deliv
nucleas
plant
cell
take
account
transfect
plasmid
rapidli
degrad
cell
endogen
nucleas
result
dna
fragment
insert
offtarget
site
host
cell
kim
et
al
deliveri
preassembl
ribonucleoprotein
rnp
plant
cell
shown
remov
possibl
introduc
recombin
dna
host
plant
genom
cho
et
al
furthermor
shown
premix
rnp
cleav
target
dna
site
immedi
transfect
degrad
rapidli
endogen
proteas
thu
reduc
frequenc
offtarget
effect
regener
plant
kim
et
al
cho
et
al
moreov
use
proteinandrnaonli
system
need
optim
codon
usag
find
promot
express
grna
deliveri
rnp
protoplast
arabidopsi
thaliana
nicotiana
attenuata
oryza
sativa
induct
target
genom
modif
regener
plant
report
purifi
protein
mix
molar
excess
grna
target
gene
three
plant
speci
vitro
obtain
preassembl
rnp
rnp
incub
protoplast
presenc
polyethylen
glycol
indel
detect
expect
posit
variou
frequenc
woo
et
al
altern
plantbas
technolog
stabl
transform
genom
transient
express
mention
stabl
transform
suitabl
rapid
product
pharmaceut
featur
would
obstacl
use
plantbas
technolog
particularli
specif
field
like
relat
product
biolog
combat
emerg
diseas
transient
technolog
platform
impli
introduct
episom
vector
plant
tissu
two
main
transient
express
strategi
first
agroinfiltr
leav
infiltr
tumefacien
inject
appli
vacuum
transfect
whole
plant
glanc
second
impli
infect
plant
tissu
directli
recombin
plant
virus
infect
cell
replic
spread
cell
cell
system
guid
express
recombin
protein
everi
cell
major
plant
viral
vector
use
base
singlestrand
rna
virus
tobacco
mosaic
viru
potato
viru
x
cowpea
mosaic
viru
cpmv
loh
et
al
use
deconstruct
viru
genom
deliv
tumefacien
methodolog
agroinfiltr
viral
infect
target
gene
clone
modifi
plant
viral
vector
integr
agrobacterium
vector
deliv
plant
tissu
infiltr
correspond
transform
agrobacterium
facilit
transfer
tdna
high
number
cell
use
deconstruct
viru
issu
instabl
viral
genom
due
introduct
larg
target
gene
resolv
moreov
certain
degre
contain
obtain
impli
transfect
mani
cell
viru
genom
follow
celltocel
movement
system
spread
peyret
lomonossoff
icon
genet
german
plant
biotechnolog
compani
adapt
technolog
manufactur
variou
plantbas
vaccin
includ
base
hepat
b
viru
surfac
antigen
mgkg
n
benthamiana
fresh
leav
form
vlp
huang
et
al
noroviru
capsid
protein
scotti
rybicki
rybicki
nonhodgkin
lymphoma
vaccin
proceed
phase
clinic
trial
see
also
tabl
mccormick
et
al
fraunhof
usa
center
molecular
biotechnolog
cmb
develop
launch
vector
advanc
hybrid
gene
infiltr
system
combin
element
tmv
vector
tumefacien
binari
plasmid
musiychuk
et
al
among
other
develop
launch
vector
contain
promot
cauliflow
mosaic
viru
camv
drive
transcript
viral
genom
nopalin
synthas
termin
gene
viru
replic
celltocel
movement
target
gene
clone
transcript
control
coat
protein
subgenom
mrna
promot
follow
infiltr
primari
transcript
produc
nucleu
transport
cytoplasm
result
robust
protein
product
mgg
fresh
weight
musiychuk
et
al
massa
et
al
peaq
system
base
fulllength
truncat
version
cpmv
effici
rapid
protein
product
without
viral
replic
sainsburi
et
al
vector
contain
camv
promot
no
termin
sequenc
encod
suppressor
silenc
cpmv
gene
interest
insert
utr
ht
hypertranslat
variant
famili
vector
provid
extrem
high
translat
effici
eventu
high
level
recombin
protein
accumul
plant
biomass
peyret
lomonossoff
transient
express
target
protein
plant
therefor
consid
feasibl
approach
compar
stabl
transform
due
rapid
product
capabl
often
lead
express
larg
amount
recombin
protein
short
time
process
scalabl
virusinfect
agroinfiltr
plant
agroinfiltr
demonstr
highest
effici
highest
level
target
protein
express
potenti
costeffect
product
loh
et
al
nicotiana
benthamiana
particularli
amen
infiltr
method
maximum
protein
express
gener
observ
within
day
postinfiltr
faster
compar
mere
viru
strategi
requir
least
week
gener
system
spread
express
mention
yield
use
approach
reach
g
product
per
kilogram
leav
though
level
obvious
proteindepend
success
clinic
trial
indic
safeti
efficaci
protein
therapeut
biolog
made
agroinfiltr
plant
see
tabl
main
exampl
repres
product
nicotiana
benthamiana
vaccin
candid
influenza
pandem
occur
canadian
compani
medicago
abl
produc
readi
administ
hemagglutininbas
vaccin
transient
express
day
daoust
et
al
product
plantbas
pharmaceut
strongli
motiv
especi
field
vaccin
effect
tool
prevent
treatment
infect
case
cancer
unfortun
progress
toward
commerci
vaccin
take
biggest
effort
time
compar
biopharmaceut
also
case
plantbas
vaccin
candid
possibl
manufactur
recombin
biopharmaceut
protein
plant
initi
gave
prospect
possibl
vaccin
deliveri
edibl
plant
materi
edibl
vaccin
haq
et
al
nevertheless
idea
vaccin
ingest
raw
plant
materi
eg
fruit
tuber
turn
feasibl
due
differ
issu
uppermost
uniform
dosag
concept
oral
antigen
deliveri
process
plant
materi
consid
feasibl
streatfield
limit
number
clinic
trial
involv
oral
deliveri
antigen
perform
case
major
safeti
concern
detect
formul
turn
well
toler
vaccine
first
trial
conduct
nontox
b
subunit
heatlabil
enterotoxin
ltb
enterotoxigen
e
coli
contain
either
raw
potato
maiz
administ
oral
healthi
volunt
safeti
immunogen
test
advers
effect
vaccin
notic
ltbspecif
igasecret
cell
peripher
blood
increas
level
ltbspecif
serum
igg
iga
detect
vaccin
tacket
et
al
tacket
noroviru
capsid
protein
produc
potato
tuber
vaccin
approxim
recombin
done
despit
high
infect
viru
result
preexist
serum
immun
portion
volunt
vaccine
develop
serum
igg
titr
tacket
et
al
also
pathogen
like
hepat
b
viru
hbv
abl
evolv
chronic
infect
cancer
adult
infant
target
pmf
hbv
surfac
antigen
hbsag
transgen
lettuc
leav
contain
g
fresh
tissu
given
three
adult
volunt
show
transient
protect
level
specif
igg
vaccin
hbsagspecif
serum
iga
kapusta
et
al
hbsag
produc
transgen
potato
thanavala
et
al
dosedepend
elev
serum
hbsag
antibodi
titr
induct
observ
administr
antigendos
clinic
trial
volunt
followup
period
first
immun
fragment
encod
chimer
protein
g
protein
n
protein
rabi
viru
fuse
alfalfa
mosaic
viru
coat
protein
introduc
tmvderiv
plant
express
vector
vaccin
transient
express
spinach
oral
administ
three
dose
spinach
g
correspond
chimer
rabi
peptid
clinic
trial
reveal
induct
elev
rabiesspecif
igg
quot
individu
previous
vaccin
commerci
injectiontyp
vaccin
volunt
histori
rabi
vaccin
yusibov
et
al
overal
studi
indic
immun
respons
mount
individu
fed
plant
materi
express
diseas
antigen
sever
antigen
express
differ
methodolog
purpos
manufactur
noned
candid
vaccin
intend
clinic
tabl
veterinari
use
tabl
plantmad
antigen
target
variou
pathogen
shown
effect
anim
model
tabl
mani
candid
reach
phase
human
clinic
trial
tabl
safeti
vaccin
demonstr
nevertheless
present
plantmad
vaccin
antigen
approv
clinic
use
despit
plantbas
express
platform
demonstr
abl
tackl
import
sanitari
problem
even
emerg
context
alreadi
explain
emerg
transient
method
assur
shortest
lead
time
final
product
major
exampl
plantmad
vaccin
clinic
trial
transient
approach
tabl
exampl
influenza
viru
complex
pathogen
differ
hemagglutinin
ha
subtyp
character
occurr
antigen
shift
abolish
crossprotect
immun
host
even
strain
subtyp
potenti
pandem
happen
influenza
viru
control
diffus
vaccin
fast
product
new
ha
antigen
need
medicago
inc
abl
develop
technolog
obtain
accumul
ha
viruslik
particl
viruslik
particl
vlp
apoplast
n
benthamiana
cell
transient
express
daoust
et
al
us
patent
applic
number
phase
subcutan
inject
twice
alum
adjuv
ii
clinic
trial
vlp
compos
ha
protein
influenza
viru
show
respect
induct
hemagglutinin
inhibit
titr
test
dose
crossprotect
tcell
respons
indic
strong
induct
longterm
cellmedi
immun
plantmad
month
vaccin
landri
et
al
detect
ige
respons
therefor
allergi
hypersensit
plantspecif
mannos
residu
found
one
main
issu
often
risen
product
proteinbas
pharmaceut
plantbas
system
ward
et
al
medicago
inc
perform
also
phase
clinic
trial
influenza
vlp
demonstr
safeti
induc
immun
respons
viru
includ
cellmedi
immun
landri
et
al
plantbas
influenza
vaccin
ha
fraunhof
cmb
usa
base
transient
express
success
complet
phase
clinic
trial
shoji
et
al
plantbas
platform
identifi
also
promis
approach
tackl
chikungunya
viru
emerg
pathogen
initi
found
east
africa
current
spread
mani
region
world
licens
vaccin
avail
thu
need
advanc
research
field
great
besid
preclin
stage
candid
trial
also
implement
parallel
lowcost
product
platform
determin
chikungunya
mainli
affect
develop
countri
access
vaccin
limit
due
high
cost
convent
formul
base
previou
experi
influenza
viral
pathogen
plantmad
vlp
seem
efficaci
approach
render
immunogen
formul
also
case
et
al
pioneer
exampl
alreadi
mention
field
edibl
vaccin
eg
hepat
b
other
undertaken
human
immunodefici
viru
lettuc
tobacco
human
papillomaviru
tomato
main
case
stabl
transform
approach
nuclear
plastidi
also
current
undertaken
evalu
preclin
context
tackl
highli
relev
sanitari
problem
relat
deadli
pathogen
like
anthrax
mustard
tobacco
ebola
viru
tobacco
see
tabl
unfortun
present
plantmad
vaccin
approv
purifi
inject
newcastl
diseas
vaccin
poultri
produc
tobacco
suspens
cell
rybicki
tabl
approv
veterinari
plantmad
vaccin
repres
quit
import
mileston
consid
plantbas
technolog
suitabl
develop
veterinari
vaccin
especi
case
fisheri
sinc
farm
reli
ocean
water
excess
use
antibiot
may
impact
environ
use
edibl
vaccin
diseas
prevent
may
mitig
problem
clark
et
al
monoclon
antibodi
mab
highli
effect
pharmaceut
cancer
therapi
gaughan
estim
market
valu
billion
http
ecker
et
al
demand
major
product
order
tonnescal
product
develop
countri
mab
consumpt
may
even
increas
suppli
biopharmaceut
extend
develop
countri
current
limit
access
biolog
due
current
cost
manufactur
mammalian
cell
cultur
scenario
would
unlock
full
potenti
plant
novel
product
platform
mab
direct
sever
tumourassoci
antigen
tabl
involv
differ
mechan
interferencediagnosi
relev
cancer
type
express
plant
leav
seed
pujol
et
al
gene
heavi
light
chain
base
format
immunoglobulin
engin
transient
stabl
express
differ
techniqu
transgenesi
involv
nuclear
chloroplast
genom
ko
et
al
komarova
et
al
daniel
mention
elsewher
chapter
everi
express
techniqu
either
stabl
transient
present
advantag
drawback
therefor
care
evalu
system
adopt
casebycas
basi
nevertheless
cumbersom
procedur
requir
establish
stabl
genom
transgen
line
literatur
highlight
express
yield
usual
noncompetit
de
muynck
et
al
transient
express
system
allow
high
yield
recombin
protein
day
transient
approach
preval
recent
year
attempt
make
plant
system
highli
product
synthesi
biolog
medicin
exampl
approach
current
possibl
produc
ten
million
dose
influenza
vaccin
remark
time
week
pillet
et
al
pioneer
work
agroinfiltr
clinic
relev
recombin
antibodi
diabodi
carcinoembryon
antigen
cea
tumour
imag
express
tobacco
plant
vaquero
et
al
valid
feasibl
approach
subsequ
studi
mgkg
yield
fullsiz
tumourspecif
human
mab
achiev
use
magnicon
system
magnifect
develop
icon
genet
giritch
et
al
marillonnet
et
al
sinc
discoveri
competit
manufactur
yield
anticanc
therapeut
antibodi
produc
plant
biosimilar
occupi
area
activ
interest
due
potenti
guarante
access
afford
treatment
also
view
patent
expiri
date
quit
number
antibodi
follow
exampl
wit
fervent
activ
sens
theracim
recombin
human
antibodi
epiderm
growth
factor
receptor
egfr
orphan
drug
statu
glioma
start
unit
state
eu
one
first
antibodi
commerci
valu
transient
express
plant
engin
aglycosyl
format
tobacco
antibodi
produc
agroinfiltr
leav
maintain
unchang
recognit
egfr
surfac
human
tumour
cultur
cell
rodriguez
et
al
trastuzumab
human
monoclon
approv
us
food
drug
administr
treatment
metastat
breast
cancer
recogn
human
epiderm
growth
factor
receptor
transient
express
n
benthamiana
plant
komarova
et
al
groh
et
al
independ
report
plantmad
mab
express
use
either
magnicon
system
tobacco
mosaic
viru
potato
viru
xbase
vector
reveal
antiprolif
effect
similarli
current
drug
herceptin
mousehuman
chimer
antibodi
rituximab
first
antibodybas
drug
approv
regulatori
author
treatment
patient
recurr
bcell
lymphoma
capabl
deplet
b
cell
vivo
reff
et
al
although
patient
treat
rituximab
respond
therapi
show
complet
remiss
tumour
davi
et
al
treatment
drug
associ
chemotherapi
pillar
treatment
nonhodgkin
lymphoma
plosker
figgitt
effort
increas
costeffect
rituximab
biolex
therapeut
use
proprietari
protein
express
lex
system
aquat
plant
lemna
minor
produc
plant
version
rituximab
fulli
humanlik
glycosyl
pattern
singl
major
nlink
glycan
devoid
xylos
fucos
cox
et
al
new
product
name
shown
target
cellbind
activ
improv
antibodydepend
cellular
cytotox
b
cell
superior
bcell
deplet
induct
apoptosi
attenu
complementdepend
cytotox
preclin
studi
gasdaska
et
al
approach
improv
efficaci
therapi
bcell
malign
base
use
antibodi
deliv
cytokin
tumour
microenviron
particular
human
interleukin
base
immunocytokin
shown
enhanc
antitumour
activ
sever
preclin
studi
list
neri
first
success
exampl
recombin
immunocytokin
produc
agroinfiltr
n
benthamiana
plant
report
unconvent
yet
effect
approach
marus
et
al
immunocytokin
design
protein
fusion
antibodi
scaffold
deriv
rituximab
human
particular
dimer
bival
antibodi
format
base
scfvfc
fuse
highli
homogen
glycosyl
devoid
typic
xylosefucos
nglycosyl
plant
signatur
vitro
studi
show
antibodi
conjug
bind
activ
compar
rituximab
effici
elicit
antibodydepend
cellmedi
cytotox
adcc
addit
context
maintain
biolog
activ
valid
bind
receptor
subsequ
trigger
tcell
prolifer
final
touch
discoveri
glycan
engin
perform
util
rnaisilenc
transgen
plant
devoid
xylosyltransferas
fucosyltransferas
activ
strasser
et
al
best
way
achiev
overal
improv
biolog
function
marus
et
al
among
antibodi
target
bcell
malign
obinutuzumab
third
gener
fulli
human
mous
monoclon
antibodi
bind
epitop
partial
overlap
rituximab
klein
et
al
obtain
proprietari
technolog
glycart
biotechnolog
develop
roch
therapeut
chronic
lymphocyt
leukaemia
bcell
nonhodgkin
lymphoma
marcu
et
al
glycoengin
mab
produc
n
benthamiana
plant
demonstr
substanti
equival
deriv
convent
chines
hamster
ovari
cho
cell
bind
expand
immunemedi
target
cell
death
lee
et
al
numer
mab
shown
potenti
treat
infecti
diseas
target
microbi
infect
directli
interact
key
epitop
andor
har
immun
respons
among
antiinfecti
mab
human
mab
recogn
distinct
neutral
epitop
envelop
protein
potent
broad
activ
vitro
vivo
hessel
et
al
due
properti
mab
chosen
pharmaplanta
consortium
http
wwwpharmaplantanet
best
candid
produc
plant
gmp
condit
first
inhuman
doubleblind
placebocontrol
random
doseescal
phase
clinic
trial
et
al
mab
repres
signific
mileston
commerci
develop
plantderiv
biolog
produc
sever
express
system
transgen
host
ie
tobacco
maiz
arabidopsi
well
plant
cell
system
howev
product
mab
transient
express
system
far
superior
obtain
stabl
transgen
term
yield
speed
express
particular
highest
yield
purifi
mab
mgkg
fresh
weight
tissu
obtain
cpmvht
system
retent
er
sainsburi
et
al
addit
bind
neutral
properti
plantproduc
human
nglycan
equival
origin
mab
deriv
cho
cell
even
effect
viru
neutral
final
siga
version
produc
transgen
n
tabacum
transient
transform
n
benthamiana
paul
et
al
demonstr
effect
aggreg
hiv
virion
enhanc
stabil
mucos
secret
compar
cognat
igg
format
antivir
mab
express
plant
human
mab
bind
epitop
envelop
protein
domain
iii
gpe
west
nile
viru
wnv
oliph
et
al
use
magnicon
system
geminivirusbas
vector
codonoptim
hc
lc
encod
sequenc
high
level
product
mg
per
kilogram
fresh
weight
achiev
n
benthamiana
lettuc
lai
et
al
effort
made
improv
mab
efficaci
engin
divers
modifi
format
transient
express
wildtyp
glycoengin
xtft
n
benthamiana
et
al
lai
et
al
overal
data
demonstr
plantmad
show
mice
strong
neutral
activ
induc
pre
postexposur
protect
equival
observ
deriv
mammalian
cell
possibl
transform
preclin
candid
costeffect
therapeut
medic
veterinari
signific
wnv
current
experiment
therapi
ebola
viru
ebov
address
princip
virul
factor
gp
transmembran
protein
trigger
viru
host
cell
entri
exert
cytopath
effect
infect
cell
lee
et
al
simmon
et
al
induc
protect
antibodi
wilson
et
al
moment
advanc
ebola
treatment
base
antibodymedi
therapi
earli
attempt
remark
express
level
mg
per
gram
fresh
tissu
protect
igg
ebola
viru
har
geminiviru
dna
replicon
bean
yellow
dwarf
viru
report
huang
et
al
time
multireplicon
vector
repres
signific
advanc
transient
express
technolog
antibodi
product
plant
previous
illustr
mapp
biopharmaceut
inc
involv
research
find
best
immunotherapi
ebola
compani
test
drug
mab
cocktail
consist
three
human
humanmous
chimer
mab
produc
cho
cell
oling
jr
et
al
produc
plant
result
three
time
effect
cho
cellproduc
recombin
counterpart
mab
like
due
absenc
core
fucos
residu
fc
region
plantderiv
mab
result
enhanc
antibodydepend
cellular
cytotox
zeitlin
et
al
nowaday
advanc
optim
antiebola
mab
composit
zmapp
cocktail
consist
select
compon
zmab
human
qiu
et
al
use
magnifect
zmapp
entir
produc
glycoengin
n
benthamiana
line
strasser
et
al
product
leafbio
san
diego
california
usa
joint
ventur
mapp
biopharmaceut
defyru
toronto
canada
manufactur
cgmp
kentucki
bioprocess
facil
although
zmapp
safeti
previous
evalu
human
ebola
outbreak
west
africa
administ
outsid
clinic
trial
compassion
use
experiment
intervent
seven
ebola
patient
postexposur
therapi
patient
five
significantli
improv
recov
diseas
even
though
treatment
initi
least
day
infect
nevertheless
random
phase
iii
clinic
trial
zmapp
put
investig
therapeut
treatment
patient
known
ebola
infect
current
underway
clinicaltrialsgov
put
investig
therapeut
treatment
patient
known
ebola
infect
stud
rec
natl
inst
health
bethesda
md
http
today
state
art
indic
zmapp
effect
drug
ebola
patient
howev
suppli
limit
provid
suffici
quantiti
biolog
challeng
due
high
dosag
requir
optim
therapi
qiu
et
al
limit
capac
plant
product
system
nevertheless
mapp
biopharmaceut
sign
contract
us
depart
health
human
servic
aim
acceler
drug
develop
mccarthi
plant
biopharm
compani
join
global
effort
ebola
medicago
quebec
canada
framework
task
order
biomed
advanc
research
develop
author
us
depart
health
human
servic
produc
three
antiebola
viru
monoclon
antibodi
mab
expect
perform
compar
parallel
fraunhof
usa
center
molecular
biotechnolog
produc
antiebov
mab
biomed
advanc
research
develop
author
calib
biotherapeut
llc
declar
readi
produc
commerci
quantiti
zmapp
mab
quickli
costeffect
overal
effort
potenti
boost
product
amount
worldwid
suppli
import
drug
paramyxoviru
respiratori
syncyti
viru
rsv
caus
devast
lower
respiratori
tract
infect
preterm
infant
small
children
elderli
patient
seriou
health
problem
present
passiv
immun
effect
immunoprophylaxi
rsv
treatment
human
mab
palivizumab
brand
name
synagi
manufactur
medimmun
current
standard
care
recent
report
plantmad
differ
isotyp
nglycoform
variant
compar
commerci
avail
palivizumab
respect
vitro
receptor
bind
vivo
efficaci
wherea
antigen
bind
neutral
activ
variant
indistinguish
palivizumab
receptor
bind
profil
demonstr
signific
differ
overal
result
indic
interact
henc
antibodydepend
cellmedi
cytotox
viru
neutral
play
major
role
palivizumab
efficaci
therefor
isotyp
glycan
profil
engin
util
glycoengin
plant
host
put
play
pave
way
enhanc
antibodydepend
cellular
cytotox
efficaci
antirsv
mab
yield
mg
per
kilogram
plant
biomass
hiatt
et
al
anthrax
zoonot
diseas
caus
gramposit
sporeform
bacterium
bacillu
anthraci
although
incid
diseas
continu
decreas
sinc
late
nineteenth
centuri
anthrax
consid
one
major
concern
era
bioterror
inhal
aerosol
spore
high
mortal
rate
b
anthraci
possess
main
virul
factor
form
protect
antigen
pa
compos
two
exotoxin
also
known
lethal
toxin
oedema
toxin
caus
cell
death
follow
introduct
cytoplasm
young
collier
pa
elicit
specif
neutral
antibodi
major
target
develop
anthrax
vaccin
mab
human
mab
b
anthraci
pa
overexpress
plant
use
prophylact
therapeut
treatment
individu
expos
infect
anthrax
human
glycosyl
eg
decor
plantspecif
glycan
glycandepriv
version
mab
devis
format
abl
bind
pa
neutral
anthrax
lethal
toxin
protect
mice
lethal
spore
challeng
surprisingli
glycandepriv
mab
demonstr
improv
halflif
provid
full
protect
nonhuman
primat
anthrax
spore
inhal
mett
et
al
infect
caus
opportunist
fungal
pathogen
pose
seriou
issu
prevent
treatment
especi
immunecompromis
hospit
individu
perspect
use
widespectrum
antifung
therapeut
chimer
complet
igg
igglik
format
scfvfc
produc
agroinfiltr
n
benthamiana
plant
capodicasa
et
al
engin
ab
deriv
murin
mab
inhibit
fungi
growth
confer
signific
protect
differ
opportunist
pathogen
candida
albican
aspergillu
fumigatu
cryptococcu
neoforman
anim
model
torosantucci
et
al
bind
fungal
cell
wall
polysaccharid
chimer
igg
scfvfc
produc
plant
retain
efficaci
origin
mab
abl
inhibit
directli
growth
candida
albican
induc
protect
anim
model
mimick
system
vagin
c
albican
infect
addit
ab
promot
kill
fungal
cell
human
polymorphonuclear
neutrophil
ex
vivo
assay
develop
recombin
iga
version
also
express
correctli
assembl
dimer
form
plant
capodicasa
et
al
recombin
ab
may
exploit
tackl
broad
rang
human
fungal
infect
altern
addit
classic
chemotherapi
tabl
current
two
product
deriv
technolog
brought
market
first
elelyso
enzym
replac
therapi
ert
human
second
interberryalpha
develop
veterinari
use
canin
gingiv
us
fda
approv
human
recombin
taligluceras
alfa
glucocerebrosidas
gc
enzym
produc
genet
engin
carrot
cell
treat
type
gaucher
diseas
gd
protalix
biotherapeut
isra
enterpris
establish
partner
pfizer
fox
gd
lysosom
storag
disord
caus
hereditari
defici
enzym
glucocerebrosidas
involv
glycolipid
metabol
gd
creat
disabl
condit
curabl
perman
ert
result
advanc
stabl
plant
transform
technolog
upstream
downstream
manufactur
process
gd
current
treat
enzym
replac
therapi
use
recombin
gc
administ
intraven
everi
week
shaaltiel
et
al
repres
altern
cheaper
choic
respect
chobas
manufactur
ie
recombin
human
gc
genzym
shire
pharmaceut
moreov
sinc
express
taligluceras
alfa
target
storag
vacuol
cell
use
plantspecif
sort
signal
determin
presenc
mannos
sugar
fact
gc
util
ert
must
display
mannos
moieti
entri
macrophag
express
process
plant
cell
result
mannos
decor
without
glycan
enzymat
remodel
instead
downstream
process
necessari
drug
mammalian
cell
origin
elev
cost
good
specif
product
protalix
brilliantli
took
advantag
plant
secretori
pathway
obtain
homogen
paucimannosid
glycan
costeffect
glycoengin
intervent
within
cell
fortun
circumst
speed
elelyso
approv
us
fda
warn
potenti
foreignparticl
contamin
genzym
product
includ
drake
et
al
event
fundament
rais
awar
scarciti
approv
safer
altern
mammalian
cell
manufactur
moreov
set
posit
exampl
follow
could
renew
investor
interest
molecular
farm
compani
similar
occur
right
commerci
approv
elelyso
determin
collabor
agreement
protalix
biotherapeuticspf
addit
posit
notic
treatment
taligluceras
allow
patient
nation
sanitari
system
estim
cost
reduct
respect
administr
imigluceras
period
also
oral
rout
administr
current
test
might
reduc
discomfort
pain
relat
intraven
administr
result
demonstr
carrot
cell
protect
recombin
protein
gastric
environ
may
enabl
absorpt
vitro
feed
rat
pig
carrot
cell
contain
gc
prove
activ
recombin
enzym
found
digest
tract
blood
reach
target
organ
shaaltiel
et
al
result
demonstr
oral
administr
protein
encapsul
plant
cell
feasibl
may
valuabl
altern
intraven
administr
ert
recombin
canin
interferonalpha
interberryalpha
produc
hokusan
co
ltd
nation
institut
advanc
industri
scienc
technolog
naist
hokkaido
japan
interberryalpha
manufactur
genet
modifi
strawberri
contain
biosafeti
level
facil
transgen
plant
avoid
gene
releas
environ
product
approv
commerci
japanes
ministri
agricultur
forestri
fisheri
process
strawberri
contain
market
treatment
periodont
diseas
dog
drake
et
al
product
proteinac
drug
vaccin
antibodi
proven
varieti
plantbas
express
platform
plant
cell
suspens
cultur
moss
duckwe
differ
applic
tabl
advanc
statu
product
reach
phase
ii
clinic
trial
hope
reach
commerci
approv
importantli
independ
method
use
stabletransi
express
current
ema
regulatori
guidelin
ema
indic
biopharmaceut
product
intend
clinic
trial
manufactur
accord
gmp
thu
gmp
complianc
appear
crucial
point
develop
plantbas
pharmaceut
clinic
use
tabl
main
gmp
factori
product
plantmad
biopharmaceut
list
besid
gmp
facil
product
plantmad
therapeut
enzym
approv
human
use
israel
protalixpf
two
big
facil
capabl
biomanufactur
plantderiv
pharmaceut
protein
gmp
condit
fraunhof
cmb
unit
state
deal
regulatori
clinic
affair
manag
gmp
pilot
plant
equip
complet
process
cycl
transient
express
ie
plant
farm
bacteri
cultur
plant
infiltr
biomass
harvest
protein
purif
also
medicago
inc
ca
clinic
trial
oper
similar
facil
pharmaceut
molecul
plantbas
biolog
may
associ
risk
particular
case
plantbas
pharmaceut
specif
featur
consid
obviou
product
free
classic
impur
describ
recombin
product
manufactur
case
biosimilar
biobett
requir
demonstr
substanti
equival
legal
market
product
mean
new
product
least
safe
effect
predic
area
plantderiv
biopharmaceut
main
safeti
issu
address
could
differ
posttransl
modif
plant
cell
nglycosyl
may
induc
allerg
respons
mainli
super
glycoengin
plant
express
see
potenti
risk
impact
environ
limit
sinc
plantbas
pharma
product
strictli
regul
mainli
envisag
gap
good
agricultur
practic
gmp
indoor
manufactur
transient
express
system
seem
pose
risk
enabl
rapid
robust
product
target
protein
requir
largescal
use
tumefacien
viral
vector
real
gmo
involv
process
therefor
agroinfiltr
cover
exist
legisl
risk
assess
gm
microorgan
plant
therefor
might
fall
scope
genet
modifi
plant
legisl
sparrow
et
al
use
system
may
allevi
regulatori
concern
relat
genet
modifi
plant
besid
crispr
also
new
plant
breed
techniqu
npbt
differ
substanti
transgen
techniqu
use
last
two
three
decad
regulatori
framework
eu
may
longer
feasibl
fact
nucleas
techniqu
use
point
mutat
nucleotid
chang
might
consid
determin
gmo
foreign
dna
integr
plant
cell
npbt
use
instead
gene
integr
cover
exist
guidanc
risk
assess
gmo
legisl
differ
integr
gene
transgenesi
even
though
greatli
enhanc
accuraci
gene
integr
target
locu
minim
unattend
side
effect
might
result
easier
risk
assess
unit
state
fda
ensur
safeti
manufactur
includ
approv
gmp
facil
plant
product
clinic
use
plantbas
biopharmaceut
licens
us
depart
agricultur
usda
also
play
role
introduct
plantmad
pharmaceut
respons
control
approv
veterinari
biolog
control
genet
background
plant
probabl
crosspollin
evalu
riskmanag
strategi
european
union
european
food
safeti
author
efsa
european
medicin
agenc
ema
charg
regul
concern
food
safeti
henc
transgen
plant
cultiv
concern
medicin
respect
ema
publish
draft
guidanc
qualiti
biolog
activ
substanc
produc
stabl
transgen
express
higher
plant
goe
plant
stabl
express
transgen
consid
transient
transfect
plant
andor
plant
cell
cultur
use
still
requir
regul
ema
state
import
establish
master
work
seed
bank
final
transform
character
respect
transgen
ie
sequenc
integr
site
insert
copi
number
fate
marker
sequenc
recombin
protein
express
ie
tissu
organ
specif
regul
express
level
unintend
chang
level
endogen
plant
protein
storag
properti
storag
condit
shelflif
importantli
ema
regulatori
guidelin
indic
biopharmaceut
product
trial
manufactur
accord
gmp
european
medicin
agenc
guidelin
qualiti
biolog
activ
substanc
produc
stabl
transgen
express
higher
plant
pharmaplanta
consortium
includ
academ
compani
europ
south
africa
fund
ce
framework
programm
first
entiti
engag
regulatori
author
field
great
merit
attribut
consortium
significantli
contribut
matur
ema
guidelin
research
area
summar
previous
text
consequ
gmp
manufactur
licens
ie
abovement
antihiv
antibodi
grant
fraunhof
ime
plantderiv
monoclon
antibodi
germani
regulatori
author
subsequ
clinic
trial
applic
approv
uk
regulatori
author
two
achiev
demonstr
gmpcompliant
process
transgen
plant
administr
plantmad
recombin
biopharmaceut
feasibl
accept
regul
throughout
europ
et
al
today
user
product
increasingli
activ
engag
consum
especi
good
relev
health
peopl
awar
consequ
health
effect
fundament
respond
peopl
expect
vast
major
consum
agre
develop
scienc
technolog
could
make
chang
live
quickli
may
hide
neg
side
effect
health
environ
castl
dalgleish
social
environment
impact
increasingli
complex
necessari
demonstr
research
ethic
social
environment
respons
biotechnolog
innov
certainli
success
technic
merit
must
also
accompani
social
accept
assum
market
demand
favour
commerci
success
word
fact
benefit
deriv
pmp
well
highlight
still
regulatori
agenc
need
cooper
develop
ensur
strict
regulatori
oversight
product
order
gain
trust
confid
support
public
concern
stakehold
investor
progress
marketplac
respons
scienc
technolog
hot
topic
among
policymak
research
innov
europ
thank
concert
effort
recent
year
peopl
understand
chang
european
research
develop
system
go
citizen
involv
scienc
public
engag
exercis
biolog
societi
scientist
establish
collabor
user
lead
innov
open
access
trend
chang
publish
system
socal
respons
research
innov
rri
fig
repres
crosscut
issu
strongli
pursu
horizon
fund
scheme
line
europ
eu
strategi
growth
launch
follow
lund
declar
updat
call
upon
european
nation
institut
focu
research
grand
challeng
face
societi
climat
chang
water
shortag
age
popul
innov
solut
improv
peopl
live
platform
better
commun
solut
address
ethic
social
environment
issu
pillar
rri
von
schomberg
area
benefit
respons
research
activ
easili
prove
health
sector
doubt
citizen
readili
welcom
result
research
affect
qualiti
life
integr
principl
respons
research
innov
research
develop
activ
field
pmp
probabl
help
improv
social
accept
plant
biotechnolog
innov
social
actor
may
motiv
particip
research
innov
process
may
discov
outcom
research
innov
field
pmp
meet
expect
safeti
desir
accept
qualiti
civil
societi
actor
encourag
work
contact
scientist
compani
deeper
level
throughout
whole
r
research
innov
process
ensur
r
result
meet
societ
expect
social
accept
suffici
import
gaug
public
attitud
toward
new
technolog
becom
import
step
market
assess
justif
financi
invest
conduct
research
develop
plantmad
biopharmaceut
intersect
among
r
area
modern
agricultur
medicin
plantssuppl
plant
biotechnolog
fig
avail
studi
show
accept
pmp
rare
combin
medic
agricultur
biotechnolog
castl
dalgleish
shown
studi
appear
posit
public
outlook
engin
pharmaceut
gener
castl
dalgleish
develop
pmp
promis
signific
advantag
product
vaccin
therapeuticprophylact
entiti
howev
benefit
risk
associ
new
technolog
must
still
commun
discuss
public
earli
maxim
social
accept
fact
abovement
studi
underlin
peopl
normal
exclud
public
debat
policymak
normal
access
data
inform
issu
media
interviewe
consid
give
mislead
inform
studi
shown
even
peopl
associ
technolog
rel
high
risk
unknown
consequ
especi
genet
technolog
still
might
reject
technolog
castl
dalgleish
oversight
regulatori
agenc
may
give
confid
gener
public
facilit
accept
new
technolog
despit
neg
percept
regard
specif
risk
empir
research
public
percept
agricultur
biotechnolog
specif
produc
novel
vaccin
pharmaceut
need
substant
gener
made
given
oral
pharmaceut
prefer
peopl
believ
vaccin
genet
modifi
public
express
high
accept
pmp
develop
technolog
commerci
parti
desir
parallel
appropri
market
demand
specif
product
invest
clear
commun
scientist
regul
enhanc
public
trust
optim
ultim
accept
pmp
even
though
first
player
tri
move
border
forward
academia
public
parti
due
commerci
uncertainti
caus
product
process
absenc
certain
regul
nevertheless
elelyso
posit
exampl
interest
engag
compani
gener
big
valu
citizen
health
reassur
peopl
possibl
get
profit
pharmaceut
biobett
natur
due
plant
origin
even
probabl
sever
risk
differ
openfield
product
food
pharmaceut
base
gmp
product
depend
plant
speci
determin
casebycas
basi
plantbas
product
evid
harmless
gm
crop
use
food
suppli
may
probabl
help
commun
endus
intrins
safeti
plantproduc
biopharmaceut
peopl
environ
exampl
metaanalysi
year
openfield
data
impact
genet
engin
maiz
clearli
demonstr
fulfil
desir
effect
target
insect
substanti
effect
insect
commun
divers
reduc
health
risk
human
consumpt
due
relev
reduct
mycotoxin
content
grain
improv
qualiti
product
pellegrino
et
al
reach
citizen
stakehold
correct
peerreview
scientif
inform
final
clear
risk
benefit
relat
genet
engin
plant
reduc
debat
hope
gene
technolog
move
forward
new
trait
new
health
properti
confer
plant
new
experiment
data
avail
allow
research
regul
draw
conclus
agroenvironment
health
risk
ge
plant
platform
pmp
differ
may
involv
use
whole
plant
greenhous
vertic
farm
facil
plant
cellorgan
cultur
subject
transient
stabl
express
target
constitut
addit
unalt
version
engin
plant
may
food
feed
crop
neither
express
may
involv
transgen
vehicul
nuclear
organel
genom
result
protein
monom
multim
viruslik
particl
pmp
may
intend
purif
administr
crude
extract
wholepl
tissu
rout
administr
may
parenter
oral
nasal
topic
aspect
may
emphas
advantag
plantbas
system
also
influenc
step
toward
commerci
process
aim
molecular
farm
produc
larg
quantiti
activ
secur
costeffect
pharmaceut
protein
approach
comparison
establish
microbi
anim
express
system
show
variou
advantag
biosynthesi
pharmaceut
biomolecul
far
lot
valuabl
pharmaceut
protein
antibodi
produc
method
help
treatment
patient
remark
develop
countri
product
preserv
cost
medicin
afford
howev
still
disput
accept
gener
public
biosecur
hurdl
end
astonish
consid
technolog
began
hypothesi
plant
cell
could
behav
reactor
newli
induc
biosynthesi
actual
result
lifesav
treatment
like
case
zmapp
elelyso
recent
past
seen
emerg
pmpbase
compani
begin
commerci
era
pmp
product
success
protalix
biotherapeut
medicago
name
one
expand
compani
field
mani
other
probabl
sustain
futur
pmp
field
look
ahead
progress
product
market
gain
wider
accept
biopharmaceut
industri
hope
